DOCSLIB.ORG

Selected Abstracts of the 13Th International Workshop on Neonatology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Selected Abstracts of the 13Th International Workshop on Neonatology www.jpnim.com Open Access eISSN: 2281-0692 Journal of Pediatric and Neonatal Individualized Medicine 2017;6(2):e060234 doi: 10.7363/060234 Published online: 2017 Oct 24 Abstracts Selected Abstracts of the 13th International Workshop on Neonatology THE POWER OF EPIGENETICS TWINS: IDENTICAL BUT DIFFERENT CAGLIARI (ITALY) • OCTOBER 25TH-28TH, 2017 The Workshop has been organized with the patronage of the Italian Society of Neonatology (SIN), the Italian Society of Pediatrics (SIP), the Italian DOHaD (Developmental Origins of Health and Disease) Society, the Italian Society of Preventive and Social Pediatrics (SIPPS), the Union of European Neonatal and Perinatal Societies (UENPS), the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), the Union of Middle-Eastern and Mediterranean Pediatric Societies (UMEMPS), the European Association of Perinatal Medicine (EAPM) and lastly the Italian-Romanian Society of Pediatrics. WORKSHOP’S PRESIDENTS Vassilios Fanos (Cagliari, Italy), Ola D. Saugstad (Oslo, Norway), Gabriel Dimitriou (Patras, Greece), Michele Mussap (Genoa, Italy), Dorret I. Boomsma (Amsterdam, The Netherlands), Raf Sciot (Leuven, Belgium), Gavino Faa (Cagliari, Italy) WORKSHOP’S HONORARY PRESIDENTS Marin Burlea (Iasi, Romania), Enver Hasanoğlu (Ankara, Turkey), Salvatore Vendemmia (Aversa, Italy) WORKSHOP’S HONORARY COMMITTEE D. Ayres-de-Campo (Porto, Portugal), S. Bernasconi (Parma, Italy), D.I. Boomsma (Amsterdam, the Netherlands), M. Burlea (Iasi, Romania), G. Buonocore (Siena, Italy), G. Corsello (Palermo, Italy), P. Curatolo (Rome, Italy), G. Di Mauro (Aversa, Italy), G. Dimitriou (Patras, Greece), C. Fabris (Turin, Italy), V. Fanos (Cagliari, Italy), G. Finco (Cagliari, Italy), H. Hasanoğlu (Ankara, Turkey), A. Iuculano (Cagliari, Italy), G. Marseglia (Pavia, Italy), G.B. Melis (Cagliari, Italy), G. Mercuro (Cagliari, Italy), G. Monni (Cagliari, Italy), C. Moretti (Rome, Italy), D. Pisano (Cagliari, Italy), G. Remuzzi (Bergamo, Italy), C. Romagnoli (Rome, Italy), E. Saliba (Tours, France), O.D. Saugstad (Oslo, Norway), M. Stronati (Pavia, Italy), G. Trapani (Sanremo, Italy), S. Vendemmia (Aversa, Italy), A. Villani (Rome, Italy), G.V. Zuccotti (Milan, Italy) WORKSHOP’S INTERNATIONAL FACULTY E. Bertino (Turin Italy), G. Buonocore (Siena, Italy), L. Cataldi (Rome, Italy), G. Corsello (Palermo, Italy), C. Dani (Florence, Italy), G. Faa (Cagliari, Italy), V. Fanos (Cagliari, Italy), G.B. Melis (Cagliari, Italy), C. Moretti (Rome, Italy), F. Mosca (Milan, Italy), P. Paolillo (Rome, Italy), M. Stronati (Pavia, Italy) SATELLITE MEETINGS’ PRESIDENTS Rino Agostiniani (Pistoia, Italy), Dorret I. Boomsma (Amsterdam, The Netherlands), Ernesto Burgio (Palermo, Italy), Gabriel Dimitriou (Patras, Greece), Gavino Faa (Cagliari, Italy), Vassilios Fanos (Cagliari, Italy), Lucia MIgliore (Pisa, Italy), Michele Mussap (Genoa, Italy), Giovanni Ottonello (Cagliari, Italy), Denis Pisano (Cagliari, Italy), Melania Puddu (Cagliari, Italy), Ola D. Saugstad (Oslo, Norway), Raf Sciot (Leuven, Belgium), Gianfranco Trapani (Sanremo, Italy) 1/89 www.jpnim.com Open Access Journal of Pediatric and Neonatal Individualized Medicine • vol. 6 • n. 2 • 2017 HOW TO CITE In the first group the level of CP was 195.3 ± 3.91 mg/l, in the second group was 224.1 ± 5.9 mg/l, p [Abstract’s authors]. [Abstract’s title]. In: Selected Abstracts < 0.05; activities of Ct were 9.6 ± 0.37 µmol/min • l of the 13th International Workshop on Neonatology; Cagliari and 6.9 ± 0.31 µmol/min • l respectively, p < 0.05; (Italy); October 25-28, 2017. J Pediatr Neonat Individual Med. activities of GTP were 68.0 ± 3.83 UI/l and 107.1 ± 2017;6(2):e060234. doi: 10.7363/060234. 1.16 UI/l respectively, p < 0.05. The activity of G6PD in the first group constituted 1.9 ± 0.06 µmol/min • Hb, ABS 1 in the second group – 1.6 ± 0.04 µmol/min • Hb, p < 0.05; GR activities were 2.1 ± 0.07 µmol/min • Hb NEONATAL ACUTE KIDNEY INJURY AND OXI- and 2.3 ± 0.06 µmol/min • Hb respectively, p > 0.05. DATIVE STRESS CONCLUSION The imbalance of the presented components of pro- A. Babintseva, Y. Hodovanets, L. Agafonova, A. oxidant system and antioxidant defense system in Phrunza critically ill full-term newborns under conditions of pathological OS is one of the triggering mechanisms Department of Pediatrics, Neonatology and Perinatal Medicine, Bukovinian of a number of pathological reactions causing the State Medical University, Chernivtsi, Ukraine formation of renal injuries in early neonatal period. REFERENCES INTRODUCTION [1] Mutinati M, Pantaleo M, Roncetti M, Piccinno M, Rizzo A, Sciorsci RL. Newborns are especially prone to oxidative stress Oxidative stress in neonatology. A Review. Reprod Dom Anim. 2014;49:7-16. (OS) [1]. OS can exacerbate several neonatal [2] Saugstad OD. Oxygen and oxidative stress in bronchopulmonary conditions to the extent that Saugstad coined the dysplasia. J Perinatal Med. 2010;38(6):571-7. phrase “oxygen radical disease of neonatology” [3] Selewski DT, Charlton JR, Jetton JG, Guillet R, Mhanna MJ, Askenazi DJ, such as bronchopulmonary dysplasia, chronic Kent AL. Neonatal Acute Kidney Injury. Pediatrics. 2015;136(3):Е463-73. lung disease, respiratory distress syndrome, peri- ventricular leukomalacia, neonatal encephalopathy, ABS 2 retinopathy of prematurity, necrotizing enterocolitis, and acute kidney injury (AKI) [2]. The objective LIFE SUPPORT MANAGEMENT IN NEONATES of this research is to study different components of WITH SEVERE OR DISMAL PROGNOSIS: THE pro-oxidant system and antioxidant defense system OPINIONS OF DOCTORS AND NURSES IN in critically ill full-term newborns with and with- A TERTIARY-LEVEL NEONATAL INTENSIVE out AKI. CARE UNIT MATERIALS AND METHODS Fifty-seven critically ill full-term neonates were S. Casarotto1, R. Beghini1, M. Castellani1, E. selected in this study. The first group included 22 Bonafiglia1, R. Frassoldati1, S. Carlassara1, F. neonates with AKI, the second group included Carnevale2, P. Biban1 35 newborns without AKI. AKI was detected according to literature [3]. The level of oxidative 1Neonatal Intensive Care Unit (NICU), Verona University Hospital, Italy modification of proteins (OMP) and concentration 2Pediatric Intensive Care Unit, McGill University, Montreal, Canada of malondialdehyde (MDA) in erythrocytes as pro- oxidant markers were established. The concentration INTRODUCTION of ceruloplasmin (CR), activities of catalase (Ct) and Advances in fetal diagnosis and postnatal medical glutamyl transpeptidase (GTP) in plasma, activities care are increasingly improving survival and offering glucose-6-phosphate dehydrogenase (G6PD) and more hope of recovery, both in extremely premature glutathione reductase (GR) in erythrocytes as anti- babies and more mature infants born with severe oxidant markers were established. clinical conditions. Thus, health professionals and RESULTS parents are frequently challenged to make complex In the first group the level of OMP was 1.16 ± 0.02 and emotionally demanding decisions, which may optical density per milliliter of erythrocytes, in the ultimately affect whether a baby shall live or die [1, 2]. second group was 1.04 ± 0.02 optical density per MATERIALS AND METHODS milliliter of erythrocytes, p < 0.05. The concentrations An anonymous online, 48-item questionnaire was of MDA in erythrocytes were 25.1 ± 0.48 µmol/l and distributed to doctors and nurses of the NICU in 24.2 ± 0.39 respectively, p > 0.05. Verona, to find out about the opinions of health 2/89 Selected Abstracts of the 13th International Workshop on Neonatology • Cagliari (Italy) • October 25th-28th, 2017 Journal of Pediatric and Neonatal Individualized Medicine • vol. 6 • n. 2 • 2017 www.jpnim.com Open Access professionals regarding the adoption of end-of-life decisions in critically ill infants. RESULTS Among the 69 recruited health professionals, we found much uncertainty about who should make end-of-life decisions. For example, while about half of the health professionals considered the Director as the final decision-maker in the NICU setting, though after multidisciplinary meetings (56.5%), in the delivery room there was a greater degree of indecision, identifying either the physician on duty (29%), the medical and nursing team (23.2%), or the Director (33.3%). Conflicts of opinion as a result of end-of-life decisions were reported by 46% of the health professionals. In evaluating 3 clinical scenarios (any patient, extreme prematurity or severe encephalopathy), we observed Strong disagreement significantly different opinions between males and females. In particular, males either strongly disagreed Disagreement or agreed in providing supportive care in each case, Uncertainty while females were in disagreement or uncertain (Fig. 1). Of note, as the age and clinical experience Agreement of health professionals increased, uncertainty about life support decisions raised. Figure 1 (ABS 2). Example of orientation of males and females in life support decisions in extremely premature CONCLUSIONS babies. Managing life support in neonates with poor or dismal prognosis is very controversial. Lack of shared scientific criteria complicates the role of the health A. Buffa1, M.C. Pintus1, M. Lussu2, A. Noto1, V. professionals. Several uncertainties and difficulties Masile1, D. Manus1, R. Pintus1, A. Dessì1, V. Fanos1, in making end-of-life decisions by NICU health L. Atzori2 professionals clearly emerged from our questionnaire. Tight collaboration between the medical and nursing 1Neonatal Intensive Care Unit, Neonatal Pathology,
Load more

Recommended publications
  • High Number of Endometrial Polyps Is a Strong Predictor of Recurrence: findings of a Prospective Cohort Study in Reproductive-Age Women
    ORIGINAL ARTICLE: GYNECOLOGY AND MENOPAUSE High number of endometrial polyps is a strong predictor of recurrence: findings of a prospective cohort study in reproductive-age women Fang Gu, M.D.,a Huanxiao Zhang, M.D.,b Simin Ruan, M.D.,c Jiamin Li, M.D.,d Xinyan Liu, M.D.,a Yanwen Xu, M.D.,a,e and Canquan Zhou, M.D.a,e a Center for Reproductive Medicine, Department of Obstetrics and Gynecology, b Division of Gynecology, Department of Obstetrics and Gynecology, and c Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, First Affiliated Hospital of Sun Yat-sen University; d Department of Obstetrics and Gynecology, Second Affiliated Hospital of Guangzhou Medical College; and e Key Laboratory of Reproductive Medicine of Guangdong Province, Guangzhou, People's Republic of China Objective: To compare the incidence of recurrence between a cohort with a high number (R6) of endometrial polyps (EPs) and a single- EP cohort among reproductive-age patients after polypectomy. Design: Prospective observational cohort study. Setting: Single university center. Patient(s): Premenopausal women who underwent hysteroscopic endometrial polypectomy were recruited. Intervention(s): Patients underwent a transvaginal ultrasound scan every 3 months after polypectomy to detect EP recurrence. Kaplan- Meier and Cox regression models were used to compare the risk of recurrence between the two cohorts and analyze the potential risk factors for EP recurrence. Main Outcome Measure(s): EP recurrence rate. Result(s): The study enrolled 101 cases with a high number of EP and 81 cases with a single EP. All baseline parameters were similar except that the high number of EP cohort had a slightly lower mean age than the single EP cohort (33.5 [range 30.0–39.0] vs.
    [Show full text]
  • ANMC Specialty Clinic Services
    Cardiology Dermatology Diabetes Endocrinology Ear, Nose and Throat (ENT) Gastroenterology General Medicine General Surgery HIV/Early Intervention Services Infectious Disease Liver Clinic Neurology Neurosurgery/Comprehensive Pain Management Oncology Ophthalmology Orthopedics Orthopedics – Back and Spine Podiatry Pulmonology Rheumatology Urology Cardiology • Cardiology • Adult transthoracic echocardiography • Ambulatory electrocardiology monitor interpretation • Cardioversion, electrical, elective • Central line placement and venous angiography • ECG interpretation, including signal average ECG • Infusion and management of Gp IIb/IIIa agents and thrombolytic agents and antithrombotic agents • Insertion and management of central venous catheters, pulmonary artery catheters, and arterial lines • Insertion and management of automatic implantable cardiac defibrillators • Insertion of permanent pacemaker, including single/dual chamber and biventricular • Interpretation of results of noninvasive testing relevant to arrhythmia diagnoses and treatment • Hemodynamic monitoring with balloon flotation devices • Non-invasive hemodynamic monitoring • Perform history and physical exam • Pericardiocentesis • Placement of temporary transvenous pacemaker • Pacemaker programming/reprogramming and interrogation • Stress echocardiography (exercise and pharmacologic stress) • Tilt table testing • Transcutaneous external pacemaker placement • Transthoracic 2D echocardiography, Doppler, and color flow Dermatology • Chemical face peels • Cryosurgery • Diagnosis
    [Show full text]
  • The Appropriate Time Interval Between Hysteroscopic Polypectomy and the Start of FET : a Retrospective Corchort Study
    The Appropriate Time Interval Between Hysteroscopic Polypectomy and the Start of FET : A Retrospective Corchort Study Zhong-Kai Wang Zhengzhou University Third Hospital and Henan Province Women and Children's Hospital Hong-Wu Qiao Zhengzhou University Third Hospital and Henan Province Women and Children's Hospital She-Ling Wu Zhengzhou University Third Hospital and Henan Province Women and Children's Hospital Wen Zhang Zhengzhou University Third Hospital and Henan Province Women and Children's Hospital Xiao-Na Yu Zhengzhou University Third Hospital and Henan Province Women and Children's Hospital Jing Li Zhengzhou University Third Hospital and Henan Province Women and Children's Hospital Xing-Ling Wang Zhengzhou University Third Hospital and Henan Province Women and Children's Hospital Hua Lou Zhengzhou University Third Hospital and Henan Province Women and Children's Hospital Yi-Chun Guan ( [email protected] ) Zhengzhou University Third Hospital and Henan Province Women and Children's Hospital https://orcid.org/0000-0002-0312-3984 Research Keywords: Endometrial polyps, hysteroscopy, polypectomy, Frozen-embryo transfer, timing Posted Date: November 19th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-110131/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/14 Abstract Objective: To investigate when is the appropriate time interval between hysteroscopic polypectomy and the start of FET cycles Design: Retrospective cohort study. Setting: Academic center. Patient(s): All patients diagnosed with endometrial polyps undergoing hysteroscopic polypectomy before FET. Intervention(s): Hysteroscopic polypectomy. MainOutcomeMeasure(s): Patients were divided into four groups based on the time interval between hysteroscopic polypectomy and the start of FET Demographics, baseline FET characteristics, pregnancy outcomes after FET were compared among the groups.
    [Show full text]
  • Post-Polypectomy Colonoscopy Surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2020
    Guideline Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2020 Authors Cesare Hassan1, Giulio Antonelli1, Jean-Marc Dumonceau2, Jaroslaw Regula3, Michael Bretthauer4,Stanislas Chaussade5, Evelien Dekker6, Monika Ferlitsch7, Antonio Gimeno-Garcia8,RodrigoJover9,MetteKalager4,Maria Pellisé10,ChristianPox11, Luigi Ricciardiello12, Matthew Rutter13, Lise Mørkved Helsingen4, Arne Bleijenberg6,Carlo Senore14, Jeanin E. van Hooft6, Mario Dinis-Ribeiro15, Enrique Quintero8 Institutions 13 Gastroenterology, University Hospital of North Tees, 1 Gastroenterology Unit, Nuovo Regina Margherita Stockton-on-Tees, UK and Northern Institute for Hospital, Rome, Italy Cancer Research, Newcastle University, Newcastle 2 Gastroenterology Service, Hôpital Civil Marie Curie, upon Tyne, UK Charleroi, Belgium 14 Epidemiology and screening Unit – CPO, Città della 3 Centre of Postgraduate Medical Education and Maria Salute e della Scienza University Hospital, Turin, Italy Sklodowska-Curie Memorial Cancer Centre, Institute of 15 CIDES/CINTESIS, Faculty of Medicine, University of Oncology, Warsaw, Poland Porto, Porto, Portugal 4 Clinical Effectiveness Research Group, Oslo University Hospital and University of Oslo, Norway Bibliography 5 Gastroenterology and Endoscopy Unit, Faculté de DOI https://doi.org/10.1055/a-1185-3109 Médecine, Hôpital Cochin, Assistance Publique- Published online: 22.6.2020 | Endoscopy 2020; 52: 1–14 Hôpitaux de Paris (AP-HP), Université Paris Descartes, © Georg Thieme Verlag
    [Show full text]
  • NOAC-Doacs Perioperative Management
    NOACS/DOACS*: PERIOPERATIVE MANAGEMENT OBJECTIVE: To provide guidance for the perioperative management of patients who are receiving a direct oral anticoagulant (DOAC) and require an elective surgery/procedure. For guidance on management of patients who require an urgent or emergency surgery/procedure, please refer to the Perioperative Anticoagulant Management Algorithm found on the Thrombosis Canada website under the “Tools” tab. BACKGROUND: Four DOACs (apixaban, dabigatran, edoxaban and rivaroxaban) are approved for clinical use in Canada based on findings from large randomized trials. The perioperative management of DOAC-treated patients aims to interrupt anticoagulant therapy (if necessary) so there is no (or minimal) residual anticoagulant effect at the time of surgery, and to ensure timely but careful resumption after surgery so as to not incur an increased risk for post- operative bleeding. There are 3 important considerations for perioperative management of patients taking a DOAC: 1) Reliable laboratory tests to confirm the absence of a residual anticoagulant effect of DOACs are not widely available. 2) Half-lives of DOACs differ and increase with worsening renal function, affecting when the drug should be stopped before surgery. 3) DOACs have rapid onset of action, with a peak anticoagulant effect occurring 1-2 hours after oral intake. In the absence of laboratory tests to reliably measure their anticoagulant effect, the perioperative administration of DOACs should be influenced by: 1) Drug elimination half-life (with normal renal function), 2) Effect of renal function on drug elimination half-life 3) Bleeding risk associated with the type of surgery/procedure and anesthesia (Table 1) 4) Whether patient is to receive spinal/epidural anesthesia EVIDENCE SUPPORTING PERIOPERATIVE MANAGEMENT OF PATIENTS TAKING A DOAC: There are emerging data relating to the efficacy and safety of the proposed perioperative management of DOAC-treated patients.
    [Show full text]
  • Risks Associated with Anesthesia Services During Colonoscopy Karen J
    Gastroenterology 2016;150:888–894 Risks Associated With Anesthesia Services During Colonoscopy Karen J. Wernli,1,2 Alison T. Brenner,2,3 Carolyn M. Rutter,1,4 and John M. Inadomi2,3 1Group Health Research Institute, Seattle, Washington; 2Department of Health Services, 3 CLINICAL AT Division of Gastroenterology, Department of Medicine, University of Washington, Seattle, Washington; 4RAND Corporation, Santa Monica, California This article has an accompanying continuing medical education activity on page e18. Learning Objective: Upon completion of this test, successful learners will be able to (1) list colonoscopy complications associated with anesthesia instead of IV conscious sedation; (2) describe geographic diversity in use of anesthesia services in performance of colonoscopy; (3) describe polypectomy complications associated with use of anesthesia for colonoscopy. Keywords: Anesthesia Services; Endoscopy; Propofol; See editorial on page 801. Gastroenterology. Watch this article’s video abstract and others at http://bit.ly/1q51BlW. BACKGROUND & AIMS: We aimed to quantify the difference Scan the quick response (QR) code to the left with your mobile device to watch this article’s in complications from colonoscopy with vs without anes- video abstract and others. Don’t have a QR code thesia services. METHODS: We conducted a prospective reader? Get one by searching ‘QR Scanner’ in ’ cohort study and analyzed administrative claims data from your mobile device s app store. Truven Health Analytics MarketScan Research Databases from 2008 through 2011. We identified 3,168,228 colonoscopy procedures in men and women, aged 40–64 years old. Colo- noscopy complications were measured within 30 days, olonoscopy is the most common colorectal cancer including colonic (ie, perforation, hemorrhage, abdominal C screening test in the United States among average- 1 pain), anesthesia-associated (ie, pneumonia, infection, com- risk adults.
    [Show full text]
  • SJH Procedures
    SJH Procedures - Gynecology and Gynecology Oncology Services New Name Old Name CPT Code Service ABLATION, LESION, CERVIX AND VULVA, USING CO2 LASER LASER VAPORIZATION CERVIX/VULVA W CO2 LASER 56501 Destruction of lesion(s), vulva; simple (eg, laser surgery, Gynecology electrosurgery, cryosurgery, chemosurgery) 56515 Destruction of lesion(s), vulva; extensive (eg, laser surgery, Gynecology electrosurgery, cryosurgery, chemosurgery) 57513 Cautery of cervix; laser ablation Gynecology BIOPSY OR EXCISION, LESION, FACE AND NECK EXCISION/BIOPSY (MASS/LESION/LIPOMA/CYST) FACE/NECK General, Gynecology, Plastics, ENT, Maxillofacial BIOPSY OR EXCISION, LESION, FACE AND NECK, 2 OR MORE EXCISE/BIOPSY (MASS/LESION/LIPOMA/CYST) MULTIPLE FACE/NECK 11102 Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); General, Gynecology, single lesion Aesthetics, Urology, Maxillofacial, ENT, Thoracic, Vascular, Cardiovascular, Plastics, Orthopedics 11103 Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); General, Gynecology, each separate/additional lesion (list separately in addition to Aesthetics, Urology, code for primary procedure) Maxillofacial, ENT, Thoracic, Vascular, Cardiovascular, Plastics, Orthopedics 11104 Punch biopsy of skin (including simple closure, when General, Gynecology, performed); single lesion Aesthetics, Urology, Maxillofacial, ENT, Thoracic, Vascular, Cardiovascular, Plastics, Orthopedics 11105 Punch biopsy of skin (including simple closure, when General, Gynecology, performed); each separate/additional lesion
    [Show full text]
  • Colon Polypectomy
    Colon Polypectomy What Is A Polypectomy? rectum and colon. If a polyp is found during your colonoscopy, your doctor can remove it during the procedure. Most of the Polyps are abnormal growths that involve the lining of the time, polyps are removed using a snare, biopsy forceps, and/ colon and grow into the inside (or the tube) of the colon or by burning the base of the polyp with an electric current. or rectum. While the majority of polyps are benign, certain This process is usually pretty quick and painless. types have the potential to become cancerous. Because of this, these growths are removed during a routine screening colonoscopy using a technique called polypectomy. A polypectomy is an important tool that doctors have for How Do I Prepare For A Polypectomy? preventing colorectal cancer, the second leading cause of Your colon must be completely cleaned out before you have cancer deaths in the US, by removing polyps before they can a colonoscopy. This gives your doctor the best chance of become cancerous. finding any polyps that you may have in your colon. To clean your colon, your doctor will give you a laxative regimen to take at home before your test, along with specific instructions to follow about how to take it. The laxative will cause significant Why Do I Need A Polypectomy? watery diarrhea, so you will need to remain close to a While most polyps are not cancerous, removing polyps bathroom after you take it. leads to a sizeable reduction in your chances of getting Also, it is common for your doctor to ask you to limit your diet colorectal cancer in the future.
    [Show full text]
  • Coverage of Colonoscopy in Nevada Under the Affordable Care Act's
    COVERAGE OF COLONOSCOPY IN NEVADA UNDER THE AFFORDABLE CARE ACT’S PREVENTION BENEFIT BACKGROUND According to the Centers for Disease Control and Prevention (CDC), Nevada’s colorectal cancer screening rate is 58%i for people ages 50-75 who report being “up-to-date” with colorectal cancer screening, far below the Healthy People 2020 goal of 70.5% or the 80% by 2018 goal set forth by the National Colorectal Cancer Roundtable. This includes having had a fecal occult blood test (FOBT) during the previous year, a sigmoidoscopy within the previous five years and a FOBT within the previous three years, or a colonoscopy within the previous 10 years.ii Each of these USPSTFiii recommended colorectal cancer screening methods are covered as a preventive service without any patient cost-sharing, such as copays or deductibles, under the Affordable Care Act’s (ACA) Essential Health Benefits.iv This requirement became effective for new plans sold or renewed on or after September 23, 2010.v Research has shown that out-of-pocket costs, such as copays, deductibles, and co-insurance, may prevent some individuals from obtaining preventive services, such as colorectal cancer screening.vi By eliminating cost-sharing for those preventive health services recommended as most effective by the USPSTF, the ACA has tried to remove barriers to these evidence-based services. However in the case of colonoscopy, there are instances when a service initiated as a preventive screening can result in unexpected cost-sharing for that patient. These instances include: 1) removal of a polyp during screening colonoscopy; 2) colonoscopy performed as part of a two-step screening following a positive stool blood test; or 3) colonoscopy performed on an individual at higher risk for colon cancer that requires earlier or more frequent screening.
    [Show full text]
  • Cervical Polypectomy During Pregnancy: the Gynaecological Perspective
    Panayotidis and Cilly, J Genit Syst Disor 2013, 2:2 http://dx.doi.org/10.4172/2325-9728.1000108 Journal of Genital System & Disorders Review Article a SciTechnol journal not routinely performed during the booking visit of the pregnancy, Cervical Polypectomy during in contrast to other European countries such as in Greece or France where a routine vaginal examination is performed at the beginning of Pregnancy: The Gynaecological any pregnancy. Perspective Therefore, it is difficult to establish whether a cervical polyp is a pre-existing condition or one that has developed during pregnancy. 1 1 Costas Panayotidis * and Latika Cilly There is no uniform universal classification for cervical polyps and many times the finding of a polyp is not documented in the patient notes as it is considered benign or clinically insignificant making a Abstract retrospective audit on clinical notes extremely difficult. The finding of a cervical polyp during pregnancy is uncommon Symptomatic women may present with vaginal bleeding, post condition. In some cases a polyp can be symptomatic, in others it is an incidental finding during vaginal examination. However in coital bleeding, vaginal discharge, cervical infection or even with both situations it can be a cause of major anxiety for the pregnant symptoms mimicking threatened preterm labour [4-6]. The degree woman. The management depends on the symptoms. Most of the of symptoms is not related to the length or the volume of the polyp. time, the conservative approach is the management of choice. In An asymptomatic polyp can be occasionally diagnosed at vaginal this article we have tried to review the recent evidence and propose a management algorithm that can be used as a guide to explain to examination during labour assessment [3].
    [Show full text]
  • Colorectal Cancer After Kidney Transplantation: a Screening Colonoscopy Case-Control Study
    biomedicines Article Colorectal Cancer after Kidney Transplantation: A Screening Colonoscopy Case-Control Study Francesca Privitera 1, Rossella Gioco 1 , Alba Ilari Civit 1, Daniela Corona 2, Simone Cremona 1, Lidia Puzzo 3, Salvatore Costa 1, Giuseppe Trama 4, Flavia Mauceri 5, Aurelio Cardella 5, Giuseppe Sangiorgio 6, Riccardo Nania 6, Pierfrancesco Veroux 7 and Massimiliano Veroux 1,7,* 1 General Surgery, University Hospital of Catania, 95123 Catania, Italy; [email protected] (F.P.); [email protected] (R.G.); [email protected] (A.I.C.); [email protected] (S.C.); [email protected] (S.C.) 2 Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy; [email protected] 3 Pathology Unit, Department of Medical and Surgical Sciences and Advanced Technologies, University of Catania, 95123 Catania, Italy; [email protected] 4 Gastroenterology Unit, University Hospital of Catania, 95123 Catania, Italy; [email protected] 5 Faculty of Medicine, University of Catania, 95123 Catania, Italy; maucerifl[email protected] (F.M.); [email protected] (A.C.) 6 Department of General Surgery and Medical-Surgical Specialties, University of Catania, 95123 Catania, Italy; [email protected] (G.S.); [email protected] (R.N.) 7 Organ Transplant Unit, University Hospital of Catania Department of Medical and Surgical Sciences and Advanced Technologies, 95123 Catania, Italy; [email protected] * Correspondence: [email protected] Citation: Privitera, F.; Gioco, R.; Civit, A.I.; Corona, D.; Cremona, S.; Abstract: The incidence of colorectal cancer in kidney transplant recipients has been previously Puzzo, L.; Costa, S.; Trama, G.; reported with conflicting results. In this study, we investigated if the incidence of colorectal ad- Mauceri, F.; Cardella, A.; et al.
    [Show full text]
  • Colonoscopic Polypectomy
    Diagnostic and Therapeutic Endoscopy, Vol. 6, pp. 111-124 (C) 2000 OPA (Overseas Publishers Association) N.V. Reprints available directly from the publisher Published by license under Photocopying permitted by license only the Harwood Academic Publishers imprint, part of The Gordon and Breach Publishing Group. Printed in Malaysia. Colonoscopic Polypectomy JEROME D. WAYE* Mount Sinai Medical Center," GI Endoscopy Unit, Mount Sinai Hospital, GI Endoscopy Unit, Lenox Hill Hospital (Received 4 October 1999," Revised 7 December 1999," In final form 21 December 1999) Colonoscopic polypectomy is a major advance in the therapy of colon neoplasms. The techniques for safe and efficient polyp removal are described. The uses of a variety of ancillary devices are discussed, including clips, loops, submucosal injection of fluid, and several thermal probes, including the argon plasma coagulator. The location of a lesion may be difficult to ascertain by intracolonic landmarks, but can be more precisely determined by X-ray, magnetic imaging, or intraoperative colonoscopy. Alternatively, it is possible to permanently mark the site of polyp removal with a carbon particle submucosal injection to facilitate subsequent localization either by surgery or interval colonoscopy. Keywords." Marking, Problems, Safety, Submucosal injection, Technique INTRODUCTION tends to separate a polyp more rapidly than does coagulation alone. Once adjusted to the optimal The removal of colonic polyps is a major advance in setting, there is no need to change the power output medicine. Polypectomy was first introduced thirty during polyp removal, regardless of whether the years ago, and it has markedly changed the way base is large or small or when switching between the polyps and cancer are treated.
    [Show full text]